Obesity; epiphenomenon or cause of metabolic syndrome?
Lois, Konstantinos, Young, J. and Kumar, Sudhesh (2008) Obesity; epiphenomenon or cause of metabolic syndrome? International Journal of Clinical Practice, Vol.62 (No.6). pp. 932-938. ISSN 1368-5031Full text not available from this repository.
Official URL: http://dx.doi.org/10.1111/j.1742-1241.2008.01773.x
Metabolic syndrome is a combination of metabolic-related health issues such as hypertension, hyperlipidaemia and hyperinsulinaemia that together increase significantly the risk of cardiovascular disease and type 2 diabetes. Its prevalence has dramatically increased over the last several decades throughout the world following that of obesity. Insulin resistance and abdominal obesity are considered its core, while the latter may generate via complex metabolic and biochemical pathways the rest parameters of metabolic syndrome. The current approach of treatment is based on treating the chronic cardiovascular malfunctions but there is increasing interest in approaches to managing abdominal obesity as the underlying cause.
|Item Type:||Journal Item|
|Subjects:||R Medicine > RC Internal medicine|
|Divisions:||Faculty of Medicine > Warwick Medical School|
|Library of Congress Subject Headings (LCSH):||Obesity -- Research, Metabolic syndrome -- Etiology, Metabolism -- Disorders|
|Journal or Publication Title:||International Journal of Clinical Practice|
|Publisher:||Wiley-Blackwell Publishing, Inc|
|Number of Pages:||7|
|Page Range:||pp. 932-938|
|Access rights to Published version:||Restricted or Subscription Access|
|References:||1 Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093– 100. 2 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 539–53. 3 Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97. 4 International Diabetes Federation. The IDF Worldwide Definition of the Metabolic Syndrome. http://www.idf.org (accessed April 2005). 5 Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059–62. 6 Zimmet P, Alberti G, Shaw J. A new IDF worldwide definition of the metabolic syndrome: the rationale and the results. Diabetes Voice 2005; 50: 32. http://www.diabetesvoice.org (accessed September 2005). 7 Greenspan FS, Gardner DG. Basic & Clinical Endocrinology. Columbus, OH: Lange Medical Books ⁄ McGraw-Hill, 2007. 8 Evans JL, Goldfine ID, Maddux BA et al. Are oxidative stress-activated signaling pathways mediators of insulin resistance and betacell dysfunction? Diabetes 2003; 52: 1–8. http://www.medscape.com (accessed January 2003). 9 Lelliott C, Vidal-Puig AJ. Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation. Int J Obes 2004; 28: S22–8. 10 DeFronzo RA, Mandarino LJ. Pathogenesis of Type 2 Diabetes Mellitus, Chapter 9. http://Endotext.com (accessed January 2003). 11 de Jongh RT, Clark ADH, Stehouwer CDA et al. Physiological hyperinsulinaemia increases intramuscular microvascular reactive hyperaemia and vasomotion in healthy volunteers. Diabetologia 2004; 47: 978–86. http://www.springerlink.com 12 Ross R, Kolka C, Rattigan S, Clark M. Acute blockade by endothelin- 1 of haemodynamic insulin action in rats. Diabetologia 2007; 50: 443–51. http://www.ingentaconnect.com/ 13 Audrey Nguyen MT, Satoh H, Olefsky JM et al. JNK and TNF-a mediated free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem. http://www.jbc.org (accessed October 2005). 14 Solinas G, Naugler W, Karin M et al. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proceedings of the National Academy of Sciences of the USA. http://www.pubmedcentral. nih.gov/ (accessed October 2006). 15 Sbarbati A, Osculati F, Maffeis C et al. Obesity and inflammation: evidence for an elementary lesion. Pediatrics 2006; 117: 220–3. http://pediatrics.aappublications.org 16 Ferrant AW. Role of Adipose Tissue Macrophages in Obesity-Induced Insulin Resistance: from Serendipity to Paradigm Shift. http:// www.the-aps.org/ (accessed 1 May 2007). 17 Jager J, Gre´meaux T, Tanti J-F et al. Interleukin-1b-induced insulin resistance in adipocytes through down regulation of insulin receptor substrate-1 expression. Endocrinology 2007; 148: 241–51. http://endo.endojournals.org/ 18 Dandona P. Obesity Causes Inflammation which Accelerates Aging. http://www.futurepundit.com (accessed September 2004). 19 Yeh ETH, Willerson JT, Calabro P, Chang D. First Link Found between Obesity, Inflammation and Vascular Disease. http:// www.eurekalert.org (accessed 19 September 2005). 20 Unger RH. The physiology of cellular liporegulation. Annu Rev Physiol 2003; 65: 333–47. 21 Ren J. Lessons from the leptin paradox in cardiac regulation – too much versus too little. J Physiol 2005; 565: 347. http://www. pubmedcentral.nih.gov/ 22 Haynes WG. Neural mechanisms in obesity-related hypertension: role of leptin in obesity-related hypertension Internet website of experimental physiology. http://ep.physoc.org/ (accessed September 2005). 23 Ehtesham NZ. Does resistin resist insulin? Curr Sci 2002; 83: 1190. http://www.ias.ac.in/. 24 Kopp H-P, Krzyzanowska K, Schernthaner G et al. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes 2005; 29: 766–71. http://www.nature.com 25 Sharma AM, Janke J, Luft FC et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. American Heart Association. Hypertension. http://www.jhypertension.com (accessed October 2002). 26 Zucker M. Sleep-disordered breathing, insulin resistance linked. Pulm Rev, 7. http://www.pulmonaryreviews.com/ (accessed July 2002). 27 Sharma AM, Bramlage P, Kirch W. Antihypertensive Effect of Irbesartan and Predictors of Response in Obesity-Associated Hypertension, Medscape Diabetes and Endocrinology. http://www.medscape. com (accessed September 2006). 28 Wolk R, Shamsuzzaman ASM, Somers VK. Obesity, Sleep Apnea, and Hypertension. American Heart Association. http://hyper. ahajournals.org (accessed November 2003). 29 Hypertension PV. Single sugars and fatty acids. J Hum Hypertens 2005; 19: S5–9. 30 Emdin M, Gastaldelli A, Ferrannini E et al. Hyperinsulinemia and Autonomic Nervous System Dysfunction in Obesity. Circulation publication. American Heart Association. http://hyper.ahajournals.org (accessed January 2001). 31 Frontoni S, Bracaglia D, Gigli F. Relationship between autonomic dysfunction, insulin resistance and hypertension, in diabetes. NCBI. http://www.ncbi.nlm.nih.gov (accessed December 2005). 32 DeFronzo RA. The effect of insulin on renal sodium metabolism. Diabetologia 1981; 21: 165–71. 33 Narkiewicz K. Obesity and hypertension – the issue is more complex than we thought. Oxford journals. Nephrol Dial Transplant 2006; 21: 264–7. http://ndt.oxfordjournals.org (accessed February 2006). 34 Hall JE, Kuo JJ, Tallam L et al. Obesity-associated hypertension and kidney disease. Medscape Diabetes Endocrinol. http://www. medscape.com (accessed March 2003). 35 Hall JE. Pathophysiology of Obesity Hypertension. NCBI. http:// www.ncbi.nlm.nih.gov (accessed 2 April 2000). 36 Praga M. Obesity – a neglected culprit in renal disease. Obesityrelated glomerulopathies – clinical features and epidemiology. Oxford journals. Nephrol Dial Transplant 2002; 17: 1157–9. http:// ndt.oxfordjournals.org (accessed July 2002). 37 Wolf G, Ziyadeh FN. Leptin and Renal Fibrosis. Contrib Nephrol 2006; 151: 175–83. 38 Moreau P, Lamarche L, Laflamme AK, Calderone A et al. Chronic hyperinsulinaemia and hypertension: the role of the sympathetic nervous system. NCBI. http://www.ncbi.nlm.nih.gov (accessed March 1995). 39 Hausberg M, Morgan DA, Haynes WG et al. Leptin potentiates thermogenic sympathetic responses to hypothermia. A receptormediated effect. Diabetes 2002; 51: 2434–40. http://diabetes. diabetesjournals.org/ 40 Enriori PJ, Evans AE, Cowley MA et al. Leptin resistance and obesity. Obesity 2006. http://www.obesityresearch.org/ 41 Furukawa S, Fujita T, Shimomura I et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752–61. http://www.jci.org 42 Bao YCX, Wang AL, Chen S et al. Studies of the association between angiotensinogen gene regulation and cytokines in essential hypertension. http://www.medscape.com (accessed October 2003). 43 Sesso HD, Wang L, Buring JE, Ridker PM, Gaziano JM. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. JAMA 2003; 290: 2945–51. 44 Jeng JR, Wang JH, Lin SZ et al. Association of interleukin-6 gene G-174C polymorphism and plasma plasminogen activator inhibitor- 1 level in Chinese patients with and without hypertension. http://www.medscape.com (accessed April 2005). 45 Urban M. Selected Cytokines (Il-6, Il-8, Il-10, MCP-1, TNF-Alpha) in Children and Adolescents with Atherosclerosis Risk Factors: Obesity, Hypertension, Diabetes. http://www.medscape.com (accessed January 2003). 46 Huang AL, Vita JA. Effects of Systemic Inflammation on Endothelium- Dependent Vasodilation. http://www.medscape.com (accessed January 2006). 47 Lonnqvist F, Thome A, Arner P et al. Pathogenic Role of Visceral Fat Beta 3-Adrenoceptors in Obesity. http://www.ncbi.nlm.nih.gov (accessed March 1995). 48 Hoffstedt J, Arner P, Hellers G, Lonnqvist F. Variation in Adrenergic Regulation of Lipolysis between Omental and Subcutaneous Adipocytes from Obese and Non-Obese Men. http://www.ncbi.nlm. nih.gov (accessed April 1997). 49 Stewart PM, Boulton A, Kumar S, Clark PMS, Shackleton CHL. Cortisol metabolism in human obesity: impaired cortisone–cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999; 84: 1022–7. 50 Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract 2007; 61: 737–47.|
Actions (login required)